Antihypertensive and metabolic effects of doxazosin in hypertensive patients with concomitant non-insulin-dependent diabetes mellitus

Journal of International Medical Research

Volumn 24, Issue 1, 1996, Pages 138-146

  Inoue, Y ^a   Kaku, K ^a   Kaneko, T ^a,g   Matsumura, S ^b   Nakayama, H ^c   Yoshizaki, Y ^c   Ando, S ^d   Inoue, M ^e   Hatao, M ^f  

^a YAMAGUCHI UNIVERSITY   (Japan)

^b Yamaguchi Pref Central Hospital   (Japan)

^c Ogori First General Hospital   (Japan)

^d Yamaguchi Saiseikai General Hospital   (Japan)

^e Onoda Red Gross Hospital   (Japan)

^f Hikari Shiritsu Hospital   (Japan)

^g Yamaguchi National Hospital   (Japan)

Author keywords

Antihypertensive agents; Diabetes mellitus; Doxazosin; Hypertension; Lipids; Non insulin dependent diabetes mellitus

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; DOXAZOSIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALE; METABOLISM; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030022644     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059602400118     Document Type: Article

References (16)

1. Williams G: Hypertension in diabetes mellitus. In: Textbook of Diabetes (Pickup J, Williams G, eds). London: Blackwell Scientific Publications, 1991; pp 719 - 732.
2. Parving HH, Andersen AR, Smidt UM, et al: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; i: 1175 - 1179.
3. Narins RG: Diabetic nephropathy: can the natural history be modified? Am J Med 1991; 90 (Suppl 2A): 70S - 75S.
4. Dupree EA, Meyer MB: Role of risk factors in the complications of diabetes mellitus. Am J Epidemiol 1980; 112: 100 -112.
5. Christlieb AR: Treatment selection considerations for the hypertensive diabetic patients. Arch Intern Med 1990; 150: 1167 - 1174.
6. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977 -986.
7. American Diabetes Association: Consensus statement: role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989; 12: 573 - 579.
8. American Diabetes Association: Position Statement: implications of the diabetes control and complications trial. Diabetes 1993; 42: 1555 - 1558.
9. The Working Group on Hypertension in Diabetes: Statement on hypertension in diabetes mellitus - final report. Arch Intern Med 1987; 147: 830 - 842.
10. Leren P, Helgeland A, Holme I, et al: Effect of propranolol and prazosin on blood lipids. Lancet 1980; ii: 4 - 6.
11. Pool JL, Taylor AA, Nelson EB: Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension. Am J Med 1989; 87 (Suppl 2A): 57S-61S.
12. Taylor SH: Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol. Am Heart J 1991; 121: 362 - 366.
13. Castrignano R, D'Angelo A, Pati T, et al: A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant non-insulin-dependent diabetes mellitus. Am Heart J 1980; 116: 1778 - 1784.
14. Feher MD, Henderson AD, Wadsworth J, et al: Alpha-blocker therapy: a possible advance in the treatment of diabetic hypertension - results of a cross-over study of doxazosin and atenolol mono-therapy in hypertensive non-insulin dependent diabetic subjects. J Hum Hypertens 1990; 4: 571 - 577.
15. Maheux P, Facchini F, Jeppesen J, et al: Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension. Comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus. Am J Hypertens 1994; 7: 416 - 424.
16. Young RA, Brogden RN: Doxazosin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in mild or moderate hypertension. Drugs 1988; 35: 525 - 541.